SG10202004557QA - Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 - Google Patents
Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9Info
- Publication number
- SG10202004557QA SG10202004557QA SG10202004557QA SG10202004557QA SG10202004557QA SG 10202004557Q A SG10202004557Q A SG 10202004557QA SG 10202004557Q A SG10202004557Q A SG 10202004557QA SG 10202004557Q A SG10202004557Q A SG 10202004557QA SG 10202004557Q A SG10202004557Q A SG 10202004557QA
- Authority
- SG
- Singapore
- Prior art keywords
- cas9
- crispr
- tracking
- cellular rna
- rna via
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562259014P | 2015-11-23 | 2015-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202004557QA true SG10202004557QA (en) | 2020-06-29 |
Family
ID=57750540
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804372PA SG11201804372PA (en) | 2015-11-23 | 2016-11-22 | Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 |
SG10202004557QA SG10202004557QA (en) | 2015-11-23 | 2016-11-22 | Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804372PA SG11201804372PA (en) | 2015-11-23 | 2016-11-22 | Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 |
Country Status (10)
Country | Link |
---|---|
US (4) | US20170145394A1 (en) |
EP (2) | EP4163374A1 (en) |
JP (2) | JP2019500899A (en) |
CN (1) | CN109072235B (en) |
AU (1) | AU2016359629B2 (en) |
CA (1) | CA3005968A1 (en) |
ES (1) | ES2930643T3 (en) |
PT (1) | PT3380613T (en) |
SG (2) | SG11201804372PA (en) |
WO (1) | WO2017091630A1 (en) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
EP3313989A4 (en) | 2015-06-29 | 2018-12-05 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and modified single crispr rna and uses thereof |
US20190225955A1 (en) | 2015-10-23 | 2019-07-25 | President And Fellows Of Harvard College | Evolved cas9 proteins for gene editing |
EP4163374A1 (en) * | 2015-11-23 | 2023-04-12 | The Regents of the University of California | Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 |
IL308426A (en) | 2016-08-03 | 2024-01-01 | Harvard College | Adenosine nucleobase editors and uses thereof |
CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
WO2018071868A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
CN110914310A (en) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | Cytosine to guanine base editor |
SG11201908658TA (en) | 2017-03-23 | 2019-10-30 | Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
EP3622062A4 (en) | 2017-05-10 | 2020-10-14 | The Regents of the University of California | Directed editing of cellular rna via nuclear delivery of crispr/cas9 |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
JP7275054B2 (en) | 2017-06-15 | 2023-05-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Targeted non-viral DNA insertion |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US10476825B2 (en) | 2017-08-22 | 2019-11-12 | Salk Institue for Biological Studies | RNA targeting methods and compositions |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
AU2018352592A1 (en) | 2017-10-16 | 2020-06-04 | Beam Therapeutics, Inc. | Uses of adenosine base editors |
US20190167815A1 (en) * | 2017-10-24 | 2019-06-06 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of rare diseases |
CN111655719A (en) | 2017-10-27 | 2020-09-11 | 加利福尼亚大学董事会 | Targeted replacement of endogenous T cell receptors |
CN107893260B (en) * | 2017-11-27 | 2021-01-12 | 广州市锐博生物科技有限公司 | Method and kit for constructing transcriptome sequencing library by efficiently removing ribosomal RNA |
CN108103090B (en) * | 2017-12-12 | 2021-06-15 | 中山大学附属第一医院 | RNA Cas9-m6A modified vector system for targeting RNA methylation, and construction method and application thereof |
CN108559760A (en) * | 2018-01-09 | 2018-09-21 | 陕西师范大学 | The method for establishing luciferase knock-in cell lines based on CRISPR targeted genomic modification technologies |
WO2019178428A1 (en) * | 2018-03-14 | 2019-09-19 | Arbor Biotechnologies, Inc. | Novel crispr dna and rna targeting enzymes and systems |
HUE063005T2 (en) | 2018-03-14 | 2023-12-28 | Arbor Biotechnologies Inc | Novel crispr dna targeting enzymes and systems |
WO2019222437A1 (en) * | 2018-05-15 | 2019-11-21 | The Children's Hospital Of Philadelphia | Crispr interference based htt allelic suppression and treatment of huntington disease |
US20210198664A1 (en) | 2018-05-16 | 2021-07-01 | Arbor Biotechnologies, Inc. | Novel crispr-associated systems and components |
EP3575401A1 (en) * | 2018-05-29 | 2019-12-04 | Ecole Polytechnique Federale De Lausanne (Epfl) | Methods of treating or preventing an aging-related disease |
US20190382759A1 (en) * | 2018-06-08 | 2019-12-19 | Locana, Inc. | Compositions and methods for the modulation of adaptive immunity |
KR20210058806A (en) | 2018-06-08 | 2021-05-24 | 로카나바이오 인크. | RNA targeting fusion protein composition and method of use |
US20210269780A1 (en) * | 2018-07-13 | 2021-09-02 | The Trustees Of Princeton University | System and method for modulating stress granule assembly |
US20210388351A1 (en) * | 2018-09-28 | 2021-12-16 | The Jackson Laboratory | Artificial rna-guided splicing factors |
CN109706149B (en) * | 2018-11-29 | 2020-12-18 | 华中农业大学 | Improved 16S-seq method and application thereof |
RU2694396C1 (en) * | 2018-12-14 | 2019-07-12 | Федеральное Бюджетное Учреждение Науки "Центральный Научно-Исследовательский Институт Эпидемиологии" Федеральной Службы По Надзору В Сфере Защиты Прав Потребителей И Благополучия Человека | RNA-CONDUCTOR St10 FOR USE IN THE HIGHLY SPECIFIC STREPTOCOCCUS THERMOPHILUS CRISPR / Cas9 (StCas9) NUCLEASES SYSTEM AND USE OF SAID RNA-CONDUCTOR AND StCas9 PROTEIN TO SUPPRESS HEPATITIS B VIRUS EXPRESSION IN THE HOST CELL AND FOR VIRAL DNA ELIMINATION FROM THE HOST CELL |
MX2021008487A (en) * | 2019-01-14 | 2021-11-12 | Univ Rochester | Targeted nuclear rna cleavage and polyadenylation with crispr-cas. |
US20220249625A1 (en) * | 2019-01-29 | 2022-08-11 | Flagship Pioneering Innovations V, Inc. | Compositions comprising an endonuclease and methods for purifying an endonuclease |
LU101118B1 (en) | 2019-02-06 | 2020-08-06 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Method for detecting a specific splice event of a gene of interest |
CN109811072B (en) * | 2019-02-28 | 2022-05-06 | 广州微远医疗器械有限公司 | CRISPR (clustered regularly interspaced short palindromic repeats) detection primer group for mycobacterium tuberculosis complex and application of CRISPR detection primer group |
WO2020191246A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
CN110004181B (en) * | 2019-03-20 | 2022-10-11 | 东北农业大学 | Additional CRISPR/Cas9 expression vector and construction method and application thereof |
WO2020198640A1 (en) * | 2019-03-27 | 2020-10-01 | Massachusetts Institute Of Technology | Programmable imaging methods and compositions |
CN110714008A (en) * | 2019-10-17 | 2020-01-21 | 南通大学 | Method for target editing ISS sequence of CRISPR recombinant plasmid constructed by nucleotide sequence |
AU2020394910A1 (en) * | 2019-12-02 | 2022-06-23 | Council Of Scientific & Industrial Research | Method and kit for detection of polynucleotide |
MX2022014008A (en) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence. |
GB202105455D0 (en) | 2021-04-16 | 2021-06-02 | Ucl Business Ltd | Composition |
EP4095243A1 (en) * | 2021-05-25 | 2022-11-30 | European Molecular Biology Laboratory | System for hybridization-based precision genome cleavage and editing, and uses thereof |
WO2023129973A2 (en) * | 2021-12-30 | 2023-07-06 | Eclipse Bioinnovations, Inc. | Methods for detecting rna modification targets on a gene |
WO2023205637A1 (en) * | 2022-04-18 | 2023-10-26 | Locanabio, Inc. | Rna-targeting compositions and methods for treating c9/orf72 diseases |
CN115044620B (en) * | 2022-06-30 | 2024-01-05 | 上海海洋大学 | Construction method and application of microsatellite repetitive sequence knockout mutant |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
NZ239247A (en) | 1990-08-03 | 1993-11-25 | Sterling Drug Inc | Oligonucleosides containing a non-phosphate inter nucleoside linkage |
US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
US5596086A (en) | 1990-09-20 | 1997-01-21 | Gilead Sciences, Inc. | Modified internucleoside linkages having one nitrogen and two carbon atoms |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
EP0691977B1 (en) | 1993-03-31 | 1997-11-26 | Sanofi | Oligonucleotides with amide linkages replacing phosphodiester linkages |
DE19502912A1 (en) | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilized Oligonucleotides |
US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
CA2303299C (en) | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
EP1071471B1 (en) | 1998-04-15 | 2008-12-31 | Fred Hutchinson Cancer Research Center | Methods and vectors for making transgenic rodents which ubiquitously express a heterologous gene |
US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
CA2372085C (en) | 1999-05-04 | 2009-10-27 | Exiqon A/S | L-ribo-lna analogues |
JP2003524637A (en) | 1999-12-23 | 2003-08-19 | エクシコン エ/エス | Therapeutic use of LNA modified oligonucleotides |
US7074557B2 (en) | 2000-03-31 | 2006-07-11 | Cambridge Antibody Technology Limited | Ribosome display |
EP2221371B1 (en) | 2007-11-22 | 2013-11-13 | Japan Science and Technology Agency | Translation regulation system in cell or artificial cell model by using low-molecular-weight rna |
US9580714B2 (en) | 2010-11-24 | 2017-02-28 | The University Of Western Australia | Peptides for the specific binding of RNA targets |
US20130276610A1 (en) | 2011-01-07 | 2013-10-24 | Bando Kiko Co., Ltd. | Method and apparatus for scribing silicon carbide plate |
WO2013058404A1 (en) | 2011-10-21 | 2013-04-25 | 国立大学法人九州大学 | Design method for rna-binding protein using ppr motif, and use thereof |
JP6317675B2 (en) * | 2011-11-30 | 2018-04-25 | サレプタ セラピューティクス, インコーポレイテッド | Oligonucleotides for treating prolonged repeat disease |
CA3179537A1 (en) | 2012-02-27 | 2013-09-06 | Amunix Pharmaceuticals, Inc. | Xten conjugate compositions and methods of making same |
IL300461A (en) * | 2012-12-12 | 2023-04-01 | Harvard College | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
DK2931897T3 (en) | 2012-12-12 | 2018-02-05 | Broad Inst Inc | CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS |
AU2014207618A1 (en) * | 2013-01-16 | 2015-08-06 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
TWI484033B (en) | 2013-01-25 | 2015-05-11 | Univ China Medical | Method and kit for culturing stem cells |
AU2014265331B2 (en) * | 2013-05-15 | 2019-12-05 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
US20160122774A1 (en) * | 2013-05-29 | 2016-05-05 | Cellectis | A method for producing precise dna cleavage using cas9 nickase activity |
EP3004339B1 (en) * | 2013-05-29 | 2021-07-07 | Cellectis | New compact scaffold of cas9 in the type ii crispr system |
KR102285485B1 (en) * | 2013-07-10 | 2021-08-04 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Orthogonal cas9 proteins for rna-guided gene regulation and editing |
EP3033424A4 (en) | 2013-08-16 | 2017-04-19 | Rana Therapeutics, Inc. | Compositions and methods for modulating rna |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US10822606B2 (en) * | 2013-09-27 | 2020-11-03 | The Regents Of The University Of California | Optimized small guide RNAs and methods of use |
US9074199B1 (en) | 2013-11-19 | 2015-07-07 | President And Fellows Of Harvard College | Mutant Cas9 proteins |
US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
BR112016013520A2 (en) | 2013-12-12 | 2017-10-03 | Broad Inst Inc | COMPOSITIONS AND METHODS OF USE OF CRISPR-CAS SYSTEMS IN NUCLEOTIDE REPEAT DISORDERS |
WO2015089277A1 (en) * | 2013-12-12 | 2015-06-18 | The Regents Of The University Of California | Methods and compositions for modifying a single stranded target nucleic acid |
CN111471674A (en) | 2014-03-05 | 2020-07-31 | 国立大学法人神户大学 | Method for modifying genome sequence of nucleic acid base for specifically converting target DNA sequence, and molecular complex used therefor |
CN105338513B (en) | 2014-08-08 | 2019-12-10 | 中兴通讯股份有限公司 | device-to-device service processing method and device |
PL3234134T3 (en) | 2014-12-17 | 2020-12-28 | Proqr Therapeutics Ii B.V. | Targeted rna editing |
WO2016106236A1 (en) * | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
US10330674B2 (en) | 2015-01-13 | 2019-06-25 | Massachusetts Institute Of Technology | Pumilio domain-based modular protein architecture for RNA binding |
WO2016183402A2 (en) | 2015-05-13 | 2016-11-17 | President And Fellows Of Harvard College | Methods of making and using guide rna for use with cas9 systems |
US20180148711A1 (en) | 2015-05-28 | 2018-05-31 | Coda Biotherapeutics, Inc. | Genome editing vectors |
WO2016196655A1 (en) | 2015-06-03 | 2016-12-08 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
CA3001683A1 (en) | 2015-06-05 | 2016-12-08 | The Regents Of The University Of California | Methods and compositions for generating crispr/cas guide rnas |
US20160362667A1 (en) | 2015-06-10 | 2016-12-15 | Caribou Biosciences, Inc. | CRISPR-Cas Compositions and Methods |
US20180142222A1 (en) | 2015-06-12 | 2018-05-24 | The Regents Of The University Of California | Reporter cas9 variants and methods of use thereof |
JP6624743B2 (en) | 2015-07-14 | 2019-12-25 | 学校法人福岡大学 | Site-specific RNA mutagenesis method, target editing guide RNA used therefor, and target RNA-target editing guide RNA complex |
WO2017053312A1 (en) | 2015-09-21 | 2017-03-30 | The Regents Of The University Of California | Compositions and methods for target nucleic acid modification |
JP6814997B2 (en) | 2015-09-21 | 2021-01-20 | トリリンク バイオテクノロジーズ エルエルシー | Compositions and Methods for Synthesizing 5'Capped RNA |
EP4163374A1 (en) * | 2015-11-23 | 2023-04-12 | The Regents of the University of California | Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 |
JP7267013B2 (en) | 2016-06-17 | 2023-05-01 | ザ・ブロード・インスティテュート・インコーポレイテッド | Type VI CRISPR orthologs and systems |
LT6525B (en) | 2016-06-29 | 2018-05-10 | Uab Pixpro | Method for the enhancement of digital image resolution by applying a unique processing of partially overlaping low resolution images |
IL308426A (en) | 2016-08-03 | 2024-01-01 | Harvard College | Adenosine nucleobase editors and uses thereof |
JP2020508056A (en) | 2017-02-22 | 2020-03-19 | クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG | Compositions and methods for gene editing |
EP3600027A4 (en) | 2017-03-31 | 2020-12-23 | Neurodiagnostics LLC | Lymphocyte-based morphometric test for alzheimer's disease |
EP3622062A4 (en) | 2017-05-10 | 2020-10-14 | The Regents of the University of California | Directed editing of cellular rna via nuclear delivery of crispr/cas9 |
US10392616B2 (en) | 2017-06-30 | 2019-08-27 | Arbor Biotechnologies, Inc. | CRISPR RNA targeting enzymes and systems and uses thereof |
US10476825B2 (en) | 2017-08-22 | 2019-11-12 | Salk Institue for Biological Studies | RNA targeting methods and compositions |
EP3684397A4 (en) | 2017-09-21 | 2021-08-18 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
CN108103090B (en) | 2017-12-12 | 2021-06-15 | 中山大学附属第一医院 | RNA Cas9-m6A modified vector system for targeting RNA methylation, and construction method and application thereof |
WO2019126762A2 (en) | 2017-12-22 | 2019-06-27 | The Broad Institute, Inc. | Cas12a systems, methods, and compositions for targeted rna base editing |
EP3781670A4 (en) | 2018-04-20 | 2021-11-10 | The Regents of the University of California | Fusion proteins and fusion ribonucleic acids for tracking and manipulating cellular rna |
WO2020047498A1 (en) | 2018-08-31 | 2020-03-05 | The Regents Of The University Of California | Directed modification of rna |
WO2020047489A1 (en) | 2018-08-31 | 2020-03-05 | The Regents Of The University Of California | Directed pseudouridylation of rna |
CN110055284A (en) | 2019-04-15 | 2019-07-26 | 中山大学 | One kind being based on PspCas13b-Alkbh5 single-gene specificity m6A modifies edit methods |
WO2020214806A1 (en) | 2019-04-16 | 2020-10-22 | The Regents Of The University Of California | Protein translational control |
-
2016
- 2016-11-22 EP EP22195456.3A patent/EP4163374A1/en active Pending
- 2016-11-22 AU AU2016359629A patent/AU2016359629B2/en active Active
- 2016-11-22 ES ES16822766T patent/ES2930643T3/en active Active
- 2016-11-22 EP EP16822766.8A patent/EP3380613B1/en active Active
- 2016-11-22 CA CA3005968A patent/CA3005968A1/en active Pending
- 2016-11-22 WO PCT/US2016/063429 patent/WO2017091630A1/en active Application Filing
- 2016-11-22 SG SG11201804372PA patent/SG11201804372PA/en unknown
- 2016-11-22 CN CN201680079817.XA patent/CN109072235B/en active Active
- 2016-11-22 PT PT168227668T patent/PT3380613T/en unknown
- 2016-11-22 SG SG10202004557QA patent/SG10202004557QA/en unknown
- 2016-11-22 JP JP2018545579A patent/JP2019500899A/en active Pending
- 2016-11-22 US US15/359,567 patent/US20170145394A1/en not_active Abandoned
-
2018
- 2018-08-03 US US16/054,298 patent/US20190040370A1/en not_active Abandoned
-
2020
- 2020-02-19 US US16/794,918 patent/US11667903B2/en active Active
-
2022
- 2022-02-18 JP JP2022023996A patent/JP2022081503A/en active Pending
-
2023
- 2023-04-25 US US18/306,673 patent/US20230365951A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2930643T3 (en) | 2022-12-20 |
CN109072235B (en) | 2023-02-28 |
EP4163374A1 (en) | 2023-04-12 |
AU2016359629B2 (en) | 2023-03-09 |
SG11201804372PA (en) | 2018-06-28 |
AU2016359629A1 (en) | 2018-06-07 |
EP3380613B1 (en) | 2022-10-26 |
JP2022081503A (en) | 2022-05-31 |
JP2019500899A (en) | 2019-01-17 |
WO2017091630A4 (en) | 2017-08-24 |
PT3380613T (en) | 2022-12-02 |
US20190040370A1 (en) | 2019-02-07 |
CN109072235A (en) | 2018-12-21 |
WO2017091630A1 (en) | 2017-06-01 |
US20230365951A1 (en) | 2023-11-16 |
CA3005968A1 (en) | 2017-06-01 |
US20170145394A1 (en) | 2017-05-25 |
EP3380613A1 (en) | 2018-10-03 |
US20200239863A1 (en) | 2020-07-30 |
US11667903B2 (en) | 2023-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10202004557QA (en) | Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 | |
EP3622062A4 (en) | Directed editing of cellular rna via nuclear delivery of crispr/cas9 | |
IL290678A (en) | Novel crispr enzymes and systems | |
HK1258288A1 (en) | Nuclease-independent targeted gene editing platform and uses thereof | |
SG11202001208XA (en) | Rna targeting methods and compositions | |
EP3374494A4 (en) | Crispr compositions and methods of using the same for gene therapy | |
IL259100A (en) | Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use | |
HK1253674A1 (en) | Compositions and methods for transient gene therapy with enhanced stability | |
EP3307762A4 (en) | Reporter cas9 variants and methods of use thereof | |
EP3313989A4 (en) | Modified crispr rna and modified single crispr rna and uses thereof | |
ZA201708498B (en) | Crispr enzyme mutations reducing off¿target effects | |
EP3359644A4 (en) | Novel rna-guided nucleases and uses thereof | |
EP3397757A4 (en) | Novel crispr-associated transposases and uses thereof | |
EP3303634A4 (en) | Cas9 variants and methods of use thereof | |
HK1259411A1 (en) | Microdroplet-based multiple displacement amplification (mda) methods and related compositions | |
EP3362104A4 (en) | Methods and compositions utilizing cpf1 for rna-guided gene editing | |
IL250744A0 (en) | Method of producing palbociclib and pharmaceutical compositions comprising the same | |
EP3245232A4 (en) | Heterodimeric cas9 and methods of use thereof | |
ZA201900225B (en) | Methods and compositions for gene expression in plants | |
HK1254608A1 (en) | Improved formulations of deferasirox and methods of making the same | |
IL255691B (en) | Methods for the storage of whole blood, and compositions thereof | |
HK1252778A1 (en) | Cell expansion methods and therapeutic compositions | |
GB201519128D0 (en) | Solid forms and methods of preparing the same | |
ZA201804779B (en) | Compositions comprising 15-hepe and methods of using the same | |
IL255178B (en) | Strigolactones or derivatives thereof for use in increasing the yeild of cultiovated plant |